Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor
about
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752The Gab1 PH domain is required for localization of Gab1 at sites of cell-cell contact and epithelial morphogenesis downstream from the met receptor tyrosine kinaseNeutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal modelsLRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergyEssential role of Gab1 for signaling by the c-Met receptor in vivoCurrent State of Animal (Mouse) Modeling in Melanoma ResearchCross-species models of human melanomaRSK isoforms in cancer cell invasion and metastasisMET: a critical player in tumorigenesis and therapeutic targetBiology of MET: a double life between normal tissue repair and tumor progressionSustained expression of naked plasmid DNA encoding hepatocyte growth factor in mice promotes liver and overall body growthDownregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma developmentARF functions as a melanoma tumor suppressor by inducing p53-independent senescenceCrk adapter proteins promote an epithelial-mesenchymal-like transition and are required for HGF-mediated cell spreading and breakdown of epithelial adherens junctions.Noncoding mutations of HGF are associated with nonsyndromic hearing loss, DFNB39.NM23 deficiency promotes metastasis in a UV radiation-induced mouse model of human melanoma.PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cellsDeficient expression of mRNA for the putative inductive factor bone morphogenetic protein-7 in chemically initiated rat nephroblastomas.A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors.Attenuated acute liver injury in mice by naked hepatocyte growth factor gene transfer into skeletal muscle with electroporation.Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial.The role of hepatocyte growth factor and its receptor c-Met in multiple myeloma and other blood malignancies.alpha2,6-hyposialylation of c-Met abolishes cell motility of ST6Gal-I-knockdown HCT116 cells.Transgenic mouse models for tumors of melanocytes and retinal pigment epithelium.Hepatocyte Growth Factor Prevented High-Fat Diet-Induced Obesity and Improved Insulin Resistance in Mice.p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells.The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment.NK1, a natural splice variant of hepatocyte growth factor/scatter factor, is a partial agonist in vivoDisassociation of met-mediated biological responses in vivo: the natural hepatocyte growth factor/scatter factor splice variant NK2 antagonizes growth but facilitates metastasis.Hepatocyte growth factor system in the mouse uterus: variation across the estrous cycle and regulation by 17-beta-estradiol and progesterone.Gene therapy for liver cirrhosis.Mammary gland neoplasia: insights from transgenic mouse models.Cancer gene discovery in hepatocellular carcinomaCombined paracrine and endocrine AAV9 mediated expression of hepatocyte growth factor for the treatment of renal fibrosisImpaired Wnt signaling in embryonal rhabdomyosarcoma cells from p53/c-fos double mutant mice.PAX3 and SOX10 activate MET receptor expression in melanoma.Oncogenic codon 13 NRAS mutation in a primary mesenchymal brain neoplasm and nevus of a child with neurocutaneous melanosis.Loss of glutathione peroxidase 3 expression is correlated with epigenetic mechanisms in endometrial adenocarcinoma.Constitutive activation of MET signaling impairs myogenic differentiation of rhabdomyosarcoma and promotes its development and progression.Vitiligo road map.
P2860
Q24541450-055124B5-A6EC-47BE-AA24-7EC8B64E931DQ24554529-E60BB5BA-142A-4780-B140-D71C10DE998BQ24629814-446A89F7-D587-4BEF-AC4E-5DB459CDADB9Q24681561-7189477C-3926-4381-AC96-06F93AB19F42Q24685688-8DCAF366-A63F-4174-93E4-A111220BC723Q26781652-DA987313-A9C5-4B63-BAAE-C4F154E794B8Q26782090-204C605F-2241-49CE-B252-13A6B7A266AFQ26827485-A66BE8F2-C86C-4852-9E91-C17BFF422FBDQ27008925-E6D2D366-9C48-4DB2-A3B5-80FE9D28C98DQ28085247-B3AE5B7A-E7D9-44DF-ACC9-FAE2DB53860BQ28210078-1D3658E0-93E3-4974-8B07-DE7A70EB1D85Q28214978-DFA8F65E-0497-4F1E-8771-766422C55006Q28591778-0680099C-1E36-4325-90F3-4C357B51005DQ30165423-78740B25-6C44-46BF-BB30-CAED00C97103Q30484106-9C0F8B0E-933E-4657-8E0E-836EA1B65D17Q30532511-00EE4273-26C9-4392-8B98-8FE28F809996Q30917936-A44FDD87-42A5-4C00-B028-4C7902D40418Q31978815-607ACDFB-B292-4B25-AB20-801E77A72A88Q33162379-93C9FD0F-1905-482E-A571-CFA2BA42BDF0Q33183473-8D85B494-2269-40CD-83EE-71B18D1A7330Q33401272-2B6217E4-DB79-466E-8395-EBD901CA9A57Q33536301-675367E3-BEBA-468C-9441-01886338DF50Q33552709-0F5C90B9-764F-4DB7-8684-3F2BD6BADE5AQ33609700-5F9BCD6C-4D46-445A-8559-2E814CC200A6Q33669422-8CC4045B-08BE-4C35-9649-6A2450C95199Q33755364-135ECC69-2FE1-4315-BC00-FFF17C70E975Q33769429-82D139F6-0600-465C-AEA9-CB694A6C105FQ33772210-348C1D08-FB09-4DD5-8D7E-B9BC8F9D2E0DQ33786959-6A60F534-1A6F-4600-AA05-01F9A2F2E0BFQ33868809-7461536C-4A61-4F72-9E61-1F3E8C37C3E3Q33888055-6E69D202-5E5F-43D6-B653-E58C8EBC3DA3Q33936692-FF5FD166-B1FD-4EE4-9031-C15C3CAFE4CEQ34002120-4B0A2A31-CA16-420B-94BD-9D729DE67074Q34025091-AEFCAD45-0114-4686-ADCA-0AE7F7FD1BB1Q34162514-0403339B-3CAF-4975-8A84-E77FBFB2119BQ34302054-D8C1AFDD-F1A2-4C76-B4A5-94E53BCD6AB3Q34402363-D34F7402-3EF8-4DB8-A813-84B93921F697Q34461690-D5437327-A9F9-488E-9BB1-DC5578DDE017Q34494731-6EC06F28-120A-4D23-9DEB-C2207A203F8DQ34511375-8F9F7EA8-E317-48F8-BBC5-E25097CB3CD0
P2860
Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Diverse tumorigenesis associat ...... e growth factor/scatter factor
@ast
Diverse tumorigenesis associat ...... e growth factor/scatter factor
@en
type
label
Diverse tumorigenesis associat ...... e growth factor/scatter factor
@ast
Diverse tumorigenesis associat ...... e growth factor/scatter factor
@en
prefLabel
Diverse tumorigenesis associat ...... e growth factor/scatter factor
@ast
Diverse tumorigenesis associat ...... e growth factor/scatter factor
@en
P2093
P2860
P356
P1476
Diverse tumorigenesis associat ...... e growth factor/scatter factor
@en
P2093
H Takayama
S A Aaronson
W J LaRochelle
P2860
P304
P356
10.1073/PNAS.94.2.701
P407
P577
1997-01-01T00:00:00Z